<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304018</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000463370</org_study_id>
    <secondary_id>UCSF-02253</secondary_id>
    <secondary_id>UCSF-H24045-21269-04</secondary_id>
    <secondary_id>UCSF-2207</secondary_id>
    <nct_id>NCT00304018</nct_id>
  </id_info>
  <brief_title>Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer</brief_title>
  <official_title>Pilot Study of Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and etoposide, before a donor
      umbilical cord blood stem cell transplant helps stop the growth of cancer cells. When the
      healthy stem cells from a donor are infused into the patient they may help the patient's bone
      marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the
      transplanted cells from a donor can make an immune response against the body's normal cells.
      Giving antithymocyte globulin before transplant and tacrolimus and prednisone after
      transplant may stop this from happening.

      PURPOSE: This phase I trial is studying how well donor umbilical cord blood transplant works
      in treating patients with advanced hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the safety and feasibility of performing donor umbilical cord blood
           transplantation (UCBT) in patients with advanced hematologic malignancies, in terms of &gt;
           80% engraftment rate at day 100 post-transplant and ≤ 50% transplant-related mortality.

      Secondary

        -  Determine the toxicity of a myeloablative preparative regimen comprising busulfan,
           fludarabine, and etoposide prior to UCBT in these patients.

        -  Determine the neutrophil and platelet recovery in patients treated with this regimen.

        -  Determine the event-free and overall survival of patients treated with this regimen.

        -  Evaluate lineage-specific chimerism after UCBT and assess the contribution of each
           individual cord blood unit to post-transplantation hematopoiesis in these patients.

        -  Determine the incidence, severity, and timing of acute and chronic graft-vs-host disease
           in patients treated with this regimen.

      OUTLINE: This is a pilot study.

        -  Preparative regimen: Patients receive fludarabine IV over 30 minutes on days -7 to -3,
           busulfan IV over 2 hours 4 times daily on days -7 and -4, etoposide IV over 4 hours on
           day -3, and anti-thymocyte globulin IV over 6 hours on days -2 and -1.

        -  Donor umbilical cord blood transplantation (UCBT): Patients undergo donor UCBT on day 0.
           Beginning on day 7, patients receive sargramostim (GM-CSF) IV or subcutaneously once
           daily until blood counts recover.

        -  Graft-vs-host disease prophylaxis: Patients receive tacrolimus IV continuously over 24
           hours or orally twice daily beginning on day -2 and continuing until day 180 followed by
           a taper. Patients also receive oral prednisone twice daily on days 13-50 and then once
           daily on days 50-60, followed by a rapid taper.

      After completion of study treatment, patients are followed periodically for approximately 2
      years.

      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety and feasibility of performing donor umbilical cord blood transplantation (UCBT) in patients with advanced hematologic malignancies</measure>
    <time_frame>up to 24 months post-transplant</time_frame>
    <description>Determine the safety and feasibility of performing donor umbilical cord blood transplantation (UCBT) in patients with advanced hematologic malignancies, in terms of &gt; 80% engraftment rate at day 100 post-transplant and ≤ 50% transplant-related mortality.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>cord blood transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following advanced hematologic malignancies:

               -  Acute myeloid leukemia (AML) meeting the following criteria:

                    -  Not expected to be curable with chemotherapy and meets ≥ 1 of the following
                       criteria:

                         -  High-risk cytogenetics (-7, -7q, -5, -5q, t[6,9], t[9,11], complex,
                            Philadelphia chromosome positive [Ph+])

                         -  AML evolved from prior myelodysplasia

                         -  AML secondary to prior chemotherapy

                         -  Failed to achieve remission

                         -  In second or subsequent remission

                    -  Marrow blasts ≤ 10% (may be achieved using chemotherapy)

               -  Myelodysplastic syndromes (MDS) with high-risk features

                    -  International Prognostic Scoring System (IPSS) score intermediate -2 or
                       high-risk

                    -  Marrow blasts ≤ 20% (may be achieved using chemotherapy)

               -  Acute lymphoblastic leukemia meeting the following criteria:

                    -  Not expected to be curable with chemotherapy and meets ≥ 1 of the following
                       criteria:

                         -  High-risk cytogenetics (Ph+, t[4,11], 11q23 abnormalities, and monosomy
                            7)

                         -  Required &gt; 1 induction course to achieve remission

                         -  Failed to achieve remission

                         -  In second or subsequent remission

                    -  Marrow blasts ≤ 10% (may be achieved using chemotherapy)

               -  Chronic myelogenous leukemia meeting ≥ 1 of the following criteria:

                    -  Accelerated phase

                    -  Chronic phase refractory to imatinib mesylate

                    -  Blastic phase

                         -  Marrow blasts ≤ 10% (may be achieved using chemotherapy)

               -  Multiple myeloma meeting 1 of the following criteria:

                    -  Stage II or III disease with &gt; first relapse or refractory disease

                    -  Newly diagnosed disease with chromosome 13 abnormalities

               -  Lymphoma meeting the following criteria:

                    -  One of the following subtypes:

                         -  Diffuse large cell lymphoma

                         -  Mantle cell lymphoma

                         -  Peripheral T-cell lymphoma

                         -  T-natural killer (NK) cell lymphoma

                         -  Hodgkin's lymphoma

                    -  Disease failed to respond to primary therapy, progressed, or recurred after
                       prior therapy

                         -  Patients who have failed autologous stem cell transplantation are
                            eligible provided it has been &gt; 1 year since transplant

          -  No rapid progression of malignant disease

          -  Not eligible for autologous stem cell transplantation

          -  Available umbilical cord blood (1-3 units) donor matching at ≥ 4 of 6 HLA antigens (A,
             B, and DR)

               -  Patients with an HLA-identical or 1 antigen-mismatched related donor OR a
                  potential HLA-matched unrelated donor matching at &gt; 6/8 (A, B, C, DR) alleles are
                  not eligible

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Creatinine &lt; 2.0 mg/dL

          -  Creatinine clearance &gt; 40 mL/min

          -  Bilirubin &lt; 2.0 mg/dL

          -  AST and alkaline phosphatase &lt; 3 times upper limit of normal

          -  Hepatitis C and active hepatitis B allowed if patient has ≤ grade 2 inflammation or
             fibrosis by liver biopsy

          -  Ejection fraction &gt; 40% by echocardiogram or MUGA

          -  DLCO &gt; 40% of predicted

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No known HIV infection

          -  No active infection requiring ongoing antibiotic treatment

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas G. Martin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

